HUTCHMED closes KRAS-EGFR license to GSK outside China
Question
HUTCHMED closes KRAS-EGFR license to GSK outside China
Direct answer
The upfront payment supports HCM cash flow and gives GSK an oncology asset with global rights outside Greater China and Taiwan. — bullish pressure on GSK via pipeline expansion via licensed KRAS-EGFR oncology rights outside Greater China and Taiwan.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-21
- Published
- 2026-10-21
- Revision
- 1 · 2026-10-21
Cite as: Market Ontology, “HUTCHMED closes KRAS-EGFR license to GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/catalysts/2026-10-21/hutchmed-closes-kras-egfr-license-to-gsk-outside-china-5b31ce
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GSK | ▲Bull | 1–4 weeks | pipeline expansion via licensed KRAS-EGFR oncology rights outside Greater China and Taiwan | 61 |
HUTCHMED closes KRAS-EGFR license to GSK outside China
The upfront payment supports HCM cash flow and gives GSK an oncology asset with global rights outside Greater China and Taiwan. — bullish pressure on GSK via pipeline expansion via licensed KRAS-EGFR oncology rights outside Greater China and Taiwan.
The source says GSK gets worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.
- SourceThe source says GSK gets worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.
- TransmissionThe upfront payment supports HCM cash flow and gives GSK an oncology asset with global rights outside Greater China and Taiwan.
- SummaryThis is a closed licensing transaction. The cash upfront is explicitly stated. The rights split is geographically defined.
- GSKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GSK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GSK price vs. pre-event level
- GSK volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China · polygon_news · 2026-10-21
Related catalysts
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21GSK gains ex-China rights to HMPL-A830GSK
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugateGSK HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830GSK HCM+0.14%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.